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Abstract
Background: The fact that the receptors for the TNF-related apoptosis inducing ligand (TRAIL) are almost invariably
expressed in colorectal cancer (CRC) represents the rationale for the employment of TRAIL-receptors targeting compounds
for the therapy of patients affected by this tumor. Yet, first reports on the use of these bioactive agents provided
disappointing results. We therefore hypothesized that loss of membrane-bound TRAIL-R might be a feature of some CRC
and that the evaluation of membrane staining rather than that of the overall expression of TRAIL-R might predict the
response to TRAIL-R targeting compounds in this tumor.
Aim and Methods: Thus, we evaluated the immunofluorescence pattern of TRAIL-receptors and E-cadherin to assess the
fraction of membrane-bound TRAIL-receptors in 231 selected patients with early-stage CRC undergoing surgical treatment
only. Moreover, we investigated whether membrane staining for TRAIL-receptors as well as the presence of KRAS mutations
or of microsatellite instability (MSI) had an effect on survival and thus a prognostic effect.
Results: As expected, almost all CRC samples stained positive for TRAIL-R1 and 2. Instead, membrane staining for these
receptors was positive in only 71% and 16% of samples respectively. No correlation between KRAS mutation status or MSI-
phenotype and prognosis could be detected. TRAIL-R1 staining intensity correlated with survival in univariate analysis, but
only membranous staining of TRAIL-R1 and TRAIL-R2 on cell membranes was an independent predictor of survival (cox
multivariate analysis: TRAIL-R1: p = 0.019, RR 2.06[1.12–3.77]; TRAIL-R2: p = 0.033, RR 3.63[1.11–11.84]).
Conclusions: In contrast to the current assumptions, loss of membrane staining for TRAIL-receptors is a common feature of
early stage CRC which supersedes the prognostic significance of their staining intensity. Failure to achieve therapeutic
effects in recent clinical trials using TRAIL-receptors targeting compounds might be due to insufficient selection of patients
bearing tumors with membrane-bound TRAIL-receptors.
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Introduction
Colorectal carcinoma (CRC) is a common malignancy account-
ing for over 1 million tumor cases worldwide and representing the
fourth tumor-related cause of death. Unfortunately, while curative
surgical therapies are feasible in patients with tumors in initial
stage, the prognosis of patients with advanced disease remains
disappointing [1].
In recent years, the advances in the understanding of the
biology of CRC have led to the establishment of several
mechanism-based therapies. Following the recognition of e.g. the
role of EGF-R and VEGF-R in proliferation and angiogenesis,
several compounds like cetuximab, panitumumab or bevacizumab
have undergone clinical investigation and were shown to positively
affect patients’ survival [2–4]. It is expected that a comprehensive
inventory of the contribution given by single signaling pathways to
carcinogenesis will allow the employment of therapies tailored to a
limited number of individual molecular targets.
Another recent instance of a mechanism-based therapy is
represented by the development of compounds targeting the
‘‘death-receptors’’ TRAIL-R1 and TRAIL-R2 to selectively
induce apoptosis in cancer cells [5]. The development of such
agents is based on the rationale provided by studies showing that
knocking out of TRAIL or blockage of TRAIL-receptors leads to
enhanced tumor and metastasis formation in vivo [6] and that loss
of TRAIL-receptors expression in human cancer tissues correlates
with poor prognosis and tumor recurrence (Reviewed by Walczak
and colleagues [7]). In this regard, we could recently show that
membrane staining for TRAIL-receptors determines the prognosis
of patients affected by hepatocellular carcinoma [8] and that the
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expression of the TRAIL-binding soluble decoy receptor OPG
correlates with tumor stage and metastasis formation in patients
affected by colon carcinoma [9]. At the present several TRAIL-
receptors targeting compounds are undergoing clinical investiga-
tion in different tumor entities [5,7].
Previous retrospective studies showing an almost invariable
staining for TRAIL-receptors in colorectal cancer samples
represented the rationale for the employment of TRAIL-receptors
targeting agents in the treatment of this tumor. Unexpectedly
however, the quantitative assessment of TRAIL-receptors staining
intensity was associated with different prognostic outcomes in
these studies [10–13]. In addition, first reports on early phase
clinical trials with TRAIL-receptors targeting compounds in CRC
showed disappointing results, prompting further investigation on a
possible role of the receptors for TRAIL as therapeutic target in
this tumor.
To address this problem we investigated a cohort of patients
with early stage colon cancer with no nodal or distant metastasis
undergoing no other treatment than surgery, and categorized
tumor samples according to the presence or absence of TRAIL-
receptors on the surface of tumor cells as an alternative to the sole
semiquantitative assessment of TRAIL-receptors staining em-
ployed in previous studies. We found that colorectal cancers show
a heterogeneous expression pattern of TRAIL receptor-1 and -2
with respect to their membranous occurrence. Differences in the
expression of TRAIL-receptors in different subcellular compart-
ments, rather than their staining intensity independently predicted
the prognosis of CRC patients, thus representing a marker
identifying a subset of tumors which have lost sensitivity to
receptor-mediated apoptosis.
Materials and Methods
Clinical samples
Colorectal cancer specimens from patients who underwent
surgical resection with curative intention between 1994 and 2004
at the University of Munich were retrieved from the archives of the
institute of Pathology of our university. Collection of samples and
of patients’ information was conducted in anonymized form in
agreement to the guidelines of the ethical committee of the
University of Munich. Only colorectal adenocarcinomas with
moderate differentiation (G2 according to the WHO classifica-
tion), T-categories T2 and T3 having neither nodal (N0) nor
distant metastasis (M0) at the time of diagnosis, and thus in stage I
and IIA according to the TNM classification of colon cancer, were
considered (T2/T3N0M0 G2) [14]. Furthermore, to minimize a
possible influence of radio- or chemo-therapy on TRAIL-receptors
status [15,16] and on patients’ prognosis, patients who underwent
neoadjuvant or adjuvant therapy in addition to surgical treatment
were excluded from this cohort. Survival data were retrieved from
the tumor registry Munich (www.tumoregister-muenchen.de).
Cases were censored where patients were lost to observation or
died due to other reasons than colorectal cancer. The study
complied with the requirements of the Ethics Committee of the
Ludwig-Maximilian Universita¨t of Munich.
Construction of tissue microarrays
Colorectal tissue microarrays (TMA) were constructed as
described previously [17]. Briefly 5 mm H&E stained sections of
formalin fixed paraffin embedded (FFPE) tumor samples were
used to define representative areas of viable tumor tissue. From
these areas 1.0 mm diameter needle core-biopsies were taken from
corresponding areas on the FFPE tumor blocks using a tissue
arrayer (Beecher Instruments, Sun Prarie, WI, U.S.A.). The cores
were placed in recipient paraffin array blocks at defined
coordinates. To ensure that representative parts of the tumors
were investigated three cores of each tumor were taken. To take
also tumor heterogeneity into account, cores were taken from
central tumor areas as well as from the invasive front. The cores in
the paraffin block were incubated for 30 min at 37uC to improve
adhesion between cores and paraffin of the recipient block.
Immunohistochemistry
Immunohistochemical staining was done on 5 mm sections of
TMA blocks. Anti-TRAIL-R1 monoclonal goat antibody (Santa
Cruz Biotechnology Inc., Heidelberg, Germany Cat.No. sc-6823),
Anti-TRAIL-R2 monoclonal rabbit antibody (Calbiochem, Cali-
fornia, U.S.A. Cat.No. PC392), E-cadherin monoclonal mouse
antibody (Invitrogen, Carlsbad, CA) were applied as primary
antibody. Coimmunofluorescence was performed using the
following fluoresceine labeled secondary antibodies: for TRAIL-
receptors FITC-conjugated anti-goat IgG (Jackson Immuno
Research laboratories, West Grove, PA) and for CDH1 a Cy3-
conjugated anti-mouse IgG (Jackson Immuno Research Labora-
tories, West Grove, PA). These antibodies were previously used
and validated [8]. Antigen retrieval was done by boiling the
sections in Target Retrieval Solution (Dako, Hamburg, Germany)
using a microwave oven 2 times each 15 min at 750 W.
Endogenous peroxidase was blocked by incubation in 7.5%
hydrogen peroxide for 10 minutes. Vectastain ABC-Kit Elite
Universal (Vector Laboratories, CA, USA) together with AEC
chromogen (Zytomed Systems) were used for development.
Finally, slides were counterstained with hematoxylin (Vector).
Evaluation of TRAIL-R1 and TRAIL-R2
immunohistochemistry
TRAIL-R1 and TRAIL-R2 immunostaining was evaluated by
grading the staining intensity according to a semiquantitative score
ranging from 0 to 2, respectively for negative, weak and strong
positive degrees of immunoreactivity (Figure 1). According to the
rationale that a prerequisite for functional activity of TRAIL-
receptors is the membranous surface expression [18], a second
evaluation was done by categorizing tumor samples according to
the presence or absence of TRAIL-receptors staining on cell
membranes regardless of the concomitant presence of cytoplas-
matic staining and its staining intensity (Figure 2). In addition to
the inspection at conventional light microscopy, to more sensitively
discriminate between membrane and cytoplasmatic staining for
TRAIL-receptors, the immunofluorescence pattern of co-staining
of TRAIL-receptors and E-cadherin was performed by using
confocal microscopy (representative staining patterns in Figure 3).
Images were captured with an LSM 700 device (Zeiss) using a Plan
Apochromat 206/0.8 M27 objective, ZEN 2009 software (Zeiss)
and the following settings: image size 204862048 and 16 bit;
pixel/dwell of 25.2 ms; pixel Size 0.31 mm; laser power 2%; master
gain 600–1000. After image capturing the original LSM files were
converted into TIFF files. To exclude intraobserver variability
specimens were evaluated twice by an observer who had no prior
knowledge of prognosis or other clinic-pathological variables.
Exemplary features of TRAIL-receptors staining in cancer
samples or in non-tumor colonic tissues are respectively shown
in Figure 1, Figure 2, and in Figure S1.
Analyses of KRAS mutations
For the analyses of mutations in exon 2 of the KRAS oncogene
in codon 12/13, material was left from only 200 of the 231
patients (86.6%). Therefore, genomic DNA was extracted from
TRAIL Receptors in Colorectal Cancer
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microdissection of tissue areas containing tumor as previously
described [19]. Pyro-sequencing was done using the Pyro-Gold kit
(Qiagen, Germany) and HotStar Taq-Polymerase (Qiagen,
Germany). The PF2 primer was used to determine anti-sense
sequences. The PyroMark Q24 device (Qiagen, Germany) and the
PyroMarkTM Q24 software were used for sequencing, and
sequence analyses [20,21].
Microsatellite stability analysis
To determine the status of microsatellite stability [microsatellite
stability (MSS) or high-grade microsatellite instability (MSIH)],
two mononucleotide repeat markers BAT-25 and BAT-26 were
investigated. DNA was amplified in a duplex PCR (Qiagen DNA
Multiplex PCR kit, 100 nM BAT25 and 100 nM BAT26-specific
primers – Table S3) applying the following cycle profile:
denaturation at 95uC for 15 min, 34 cycles of denaturation at
94uC for 30 sec, annealing at 57uC for 90 sec and extension at
72uC for 60 sec, with a final extension step at 60uC for 30 min, as
previously described [22,23]. 1 ml of the PCR product was mixed
with 18.5 ml of highly deionized formamide (HiDi formamide) and
0.5 ml DNA Size Standard LIZ 500 / (2250) (both Applied
Biosystems, Darmstadt, Germany). This mixture was denaturated
for 3 min at 94uC, immediately put on ice, and separated using an
Figure 1. Semiquantitative evaluation of TRAIL-R1 and TRAIL-R2 staining in CRC cells. (A) Percentage of samples showing no staining,
weak or strong immunoreactivity. (B–D): representative typical microscopic appearance of TRAIL-R1 staining (B: no staining. C: weak and D: strong
staining). (D to F): staining of TRAIL-R2 (E: no staining. F: weak and G: strong staining). The present sections are representative of a grade 2 colonic
cancer in stage II (T3N0M0) at the magnification of 6306.
doi:10.1371/journal.pone.0051654.g001
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ABI 3130 Genetic Analyzer. Results were analysed using
GeneMapper Software (Applied Biosystems).
Analysis of the expression of the splice forms KRAS4A
and KRAS4B
For this investigation sufficient material was left for only 128 of
231 tumor samples (55.4%). Therefore whole RNA was isolated
from microdissected tumor areas using RNeasy kits (Qiagen;
74404) as previously described [24]. RNA concentrations were
measured by UV-photometry. 200–1000 ng of RNA isolates were
reverse transcribed in the presence of 100 mM random hexamer
primers and of 200 U RevertAid Reverse Transcriptase (both by
Fermentas, St. Leon, Germany; SO142, EP0441). 2 ml of the
crude RT-reaction were used as the template in RT-qPCRs
employing Light Cycler 480 Probes Master (Roche; 04902343001)
with specific primer-pairs and Universal ProbeLibrary Probes
(Roche – Table S3). Cp (critical point) values of RT-qPCRs
specific for KRAS4A, KRAS4B and the reference gene HPRT (hypo-
xanthin phosphoribosyl- transferase) were determined employing a
LightCycler 480 device (Roche). All concentrations of KRAS4A,
KRAS4B -specific RNAs were normalized on the expression of the
HPRT gene (DCp). Experiments were done in duplicates and
repeated at least twice. To validate the experimental system,
relative amounts of the two splice variants KRAS4A and KRAS4B
were assessed in cell lines SW948 and HCT15 as it had been
described that SW948 express more KRAS4A variant than
HCT15 cells [25]. This result was reproducible (Figure S3) thus
validating the experimental set-up. Moreover, our read out system
demonstrated high robustness as calibration curves using defined
amounts of template DNA showed linearity at least over four log
scales down to 100 copies of the specific type of RNA (Figure S3).
Statistical analysis
Cross-tabulations were calculated using Fisher’s exact test.
Kaplan-Meier analysis was used to estimate cancer specific
survival. Significance of the Kaplan-Meier statistic was tested
applying the log-rank test. Multivariate analysis was done by using
the multivariate Cox regression model. Statistics were calculated
using SPSS version 15.0 (SPSS Inc.). p-values,0.05 were
considered to be statistically significant.
Figure 2. TRAIL-R1 and TRAIL-R2 staining in human colorectal cancer. (A) percentage of tumor samples showing membrane staining for
TRAIL-R1 and TRAIL-R2. Representative typical microscopic appearance of TRAIL-R1 staining with predominant cytoplasmatic (B) or membrane
staining (C). Typical pattern of TRAIL-R2 staining with predominant cytoplasmatic staining (D) or membrane staining (E). Magnification,6800. The
present sections are representative of a grade 2 colonic cancer in stage II (T3N0M0) at the magnification of 6306.
doi:10.1371/journal.pone.0051654.g002
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Results
Patients and samples
The screening for cancer specimens was conducted in patients
who underwent surgical resection with curative intention between
1994 and 2004 at our institution. The selection of samples was
limited to colorectal adenocarcinomas with moderate differentia-
tion (G2), T-categories T2 and T3 in patients having neither nodal
(N0) nor distant metastasis (M0) at the time of diagnosis, and
limited to patients receiving surgical treatment only. This resulted
in a collection of 231 patients for the analysis. The collection
consisted of 55% male and 45% female patients. 64% of the
patients were older than 65 years (mean age 5668.1 years) while
the remaining 36% of patient had a mean age of 7566.9 years.
85% of patients were diagnosed with a tumor in stage T3 while
15% of patients were affected by a tumor in stage T2. The survival
data was censored as case follow up was discontinued or patients
died for other reasons than colorectal cancer. The characteristics
of this patient population are summarized in Table 1.
TRAIL-R1 and TRAIL-R2 staining in colorectal cancer
samples
To assess the staining of TRAIL-receptors in tumor samples we
first performed a semi-quantitative analysis based on the
categorization of samples according to the absence of staining,
or the presence of a weak or strong staining intensity for the
respective receptors. According to this criterion, 87 (38%) of colon
cancer samples showed a strong positive staining, 129 (56%)
showed a weak staining, whereas 15 (6%) samples stained
altogether negative for TRAIL-R1 (Figure 1). As TRAIL-R2 in
tumor samples was examined, a strong staining was observed in
110 (48%) of cases, a weak staining in 116 (50%), while only 5 (2%)
samples stained negative for TRAIL-R2 (Figure 1). In a
subsequent analysis we determined the cellular distribution of
TRAIL-R1 and TRAIL-R2 by categorizing tumor samples
according to the presence or absence of staining for the respective
TRAIL-receptors on the cell membranes. As judged by immuno-
histochemical staining and the overlapping immunofluorescence
pattern of TRAIL-receptors and of E-cadherin, membrane
Figure 3. Membranous localization of TRAIL-receptors and E-cadherin. Representative pattern of co-staining of TRAIL-R1 and E-Cadherin on
cell membranes of colorectal cancer cells by confocal microscopy showing (A) a pattern of predominant membrane staining vs. (B) non membranous
staining. Staining for TRAIL-R1 (green, left panel), E-cadherin (red, middle panel) and overlays of these staining (right panel).
doi:10.1371/journal.pone.0051654.g003
Table 1. Clinical and pathological characteristics of CRC
patients.
Variable N (%)
Gender
Male 126 (55%)
Female 105 (45%)
Age, y
,65 84 (36%)
$65 147 (64%)
T-category
T2 34 (15%)
T3 197 (85%)
KRAS status
No mutation 74 (37%)
Mutation 126 (63%)
MSI-phenotype
Instable 69 (35%)
Stabie 126 (65%)
doi:10.1371/journal.pone.0051654.t001
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staining for TRAIL-R1 could be detected in 163 (71%) cases,
whereas negative staining or exclusively cytoplasmatic staining was
found in 68 (29%) cases. For TRAIL-R2 membrane staining was
observed in 36 cases (16%); cytoplasmatic or negative staining was
observed in 195 cases (84%).
Therefore, while most tumor samples stained altogether positive
for TRAIL-receptor 1 and 2, the fraction of tumor samples
showing membrane staining for these receptors was considerably
lower. When the expression intensity and the cellular distribution
of TRAIL-receptors on tumor samples were analyzed in relation
to different clinico-pathological variables including KRAS-muta-
tion status and the presence of microsatellite instability, no
correlation could be detected as judged by Fisher’s exact test
(Tables S1 and S2).
Prognostic significance of TRAIL-receptor expression and
cellular localization in colorectal cancer
When the expression of TRAIL-receptors was considered in
relation to the survival of colorectal cancer patients, TRAIL-R1
staining intensity (high expression vs. low/no expression) was
associated with a significantly better prognosis: the 5-year survival
of patients bearing tumors with overall higher TRAIL-R1
expression was 70% vs. 56% of patients with low or altogether
no staining for TRAIL-R1; the 10-year survival for these patients
was respectively 31% vs. 25% (p= 0.008; Figure 4A). Additionally,
when tumor samples were categorized according to the presence
or absence of membrane staining for TRAIL-receptors, patients
with tumors exhibiting TRAIL-R1 staining on the surface of cell
membranes were shown to have a better prognosis vs. patients
with cytoplasmatic or no staining (5- year survival 65% vs. 44%;
10-year survival: 30% vs. 22%, p= 0.003 – Figure 4B).
When TRAIL-R2 staining was considered, its intensity of
expression did not significantly correlate with survival (p = 0.17;
Figure 4C). However, if patients were stratified according to the
presence or absence of staining on the cell membranes, membrane
staining for TRAIL-R2 in tumor samples correlated with a
significantly better patient survival (5-year survival: 83% vs. 57%;
10-year survival: 38% vs. 26% p=0.015; Figure 4D). When
patients’ survival was analyzed according to the double positivity
for TRAIL-receptors, i.e. when the survival of patients with
simultaneous membrane staining for TRAIL-R1 and TRAIL-R2
was compared to that of patients exhibiting no staining or
cytoplasmatic staining only, the survival of patients with
membrane staining for both TRAIL-receptors increased to 92%
vs. 44% of patients with no membranous staining (p = 0.012,
Figure 4E). A further analysis considering the possibly that, as
previously reported, KRAS mutations, a decreased amount of the
splicing variant KRAS4A relative to the splice variant KRAS4B,
or an MSI-phenotype might influence the survival of colorectal
cancer patients [26–28], failed to show any significant prognostic
effect in our patients’ cohort (Figure S2).
Finally, to assess the specific influence of TRAIL-receptors
staining on survival, a Cox regression analysis including simulta-
neously the cellular distribution of TRAIL-receptors, their staining
intensity and other relevant clinico-pathological variables was
performed. This showed that membrane staining for TRAIL-R1
and for TRAIL-R2 individually and independently predicts the
survival of our colorectal cancer patients collective (TRAIL-R1:
p = 0.019, RR 2.06 [1.12–3.77]; TRAIL-R2: p = 0.033, RR 3.63
[1.11–11.84]). In contrast, in spite of the significant association
found in the long-rank test, the staining intensity/expression of
TRAIL-receptors could not be confirmed as independent risk
factor for recurrence (Table 2).
Discussion
TRAIL-receptors in the pathophysiology and therapy of
colorectal cancer
The loss of TRAIL-receptors has been shown to play an
important role in cancer development. In particular, several
different studies support the notion that TRAIL signaling plays in
vivo an important function in preventing metastasis formation [29–
32]. Recently it was also shown that the expression of TRAIL-
receptors correlates with that of several markers of apoptosis thus
providing a link between the functional role of these receptors and
their prognostic significance [33].
Previous reports on the almost ubiquitous expression of TRAIL-
receptors in CRC represented the rationale for the use of TRAIL-
receptors targeting agents for the treatment of this tumor.
Surprisingly however, while the frequent loss of TRAIL-receptors
reported for several tumor entities might represent an obstacle to
the clinical efficacy of such compounds [8,10,34,35] no systematic
evaluation of membrane staining of TRAIL-receptors in CRC
samples is available. Furthermore, first reports on early phase
clinical trials with TRAIL-receptors targeting agonistic antibodies
in CRC failed to show clear signs of efficacy [36] prompting
further investigation on TRAIL-receptors as therapeutic target in
the treatment of this tumor. To address this issue, basing on our
recent findings in hepatocellular carcinoma [8] we adopted the
evaluation of the cellular distribution of TRAIL-receptors as
criterion for evaluating their prognostic significance. Also, to
reduce potential biasing factors, we decided to analyze a
homogenous patient collective with tumors in early stage with
no metastasis undergoing surgery only.
Prognostic relevance of TRAIL-receptors staining
intensity
In agreement with previous studies [10,12,13], in our cohort the
vast majority of samples showed positive staining for TRAIL-R1
and TRAIL-R2, roughly half of samples showing a strong staining
(Figure 1). As we assessed the prognostic significance of TRAIL-
receptors staining, TRAIL-R1 intensity staining scores (strong vs.
low/no-staining) showed a significant correlation with survival in
the long-rank test, higher TRAIL-R1 staining intensity being
associated with better survival (p = 0.008, Figure 4A); in contrast,
TRAIL-R2 staining intensity, KRAS-status, the relative amount of
the splice variant KRAS4A or MSI-phenotype showed no
correlation with survival (Figure 4C, Figure S2). These results
are in agreement with previous studies which reported a positive
correlation between patients’ survival and expression of TRAIL-
R1 [10,33]. For unknown reasons, no effect [13] or even a
negative correlation for TRAIL-R1 but trendy positive correlation
for TRAIL-R2 with survival were also reported [12].
Prognostic relevance of the cellular distribution of TRAIL-
receptors as alternative to staining intensity
In the attempt to further clarify this issue, we subsequently
evaluated whether the presence or absence of membrane staining
of TRAIL-receptors could better correlate with survival then the
sole evaluation of their staining intensity. In contrast to the almost
ubiquitous staining for TRAIL-receptors, a considerable fraction
of samples showed negative membrane staining for TRAIL-R1
and TRAIL-R2 (Figure 2). By adopting this criterion, five-year
survival in patients bearing tumors exhibiting TRAIL-R1 or
TRAIL-R2 staining on cell membranes was higher than that of
patients showing no staining or cytoplasmatic staining only
(Figure 4). Patients bearing tumors with double-positive mem-
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brane staining for both TRAIL-receptors survived significantly
longer in comparison to patients showing double-negative
membrane staining (Figure 4E). The fact that in the multivariate
analysis comprising the effect of the cellular distribution of
TRAIL-receptors as well as that of their staining intensity, the
latter could not be confirmed as independent prognostic factor
suggests that the detection of TRAIL-receptors staining on cell
membrane is the major determinant of survival: this is consistent
with the data available for patients affected by hepatocellular
carcinoma [8], with recent in vitro evidence on the role of TRAIL-
receptors internalization in the resistance to TRAIL [18], and with
the notion that membrane-bound TRAIL-receptors are exposed
to the effect of circulating TRAIL. Previous studies had shown no
prognostic significance for TRAIL-R2, or only a trend toward a
positive correlation between the expression of this receptor and
survival [12]; we hypothesize that failure to recognize the role of
Figure 4. TRAIL-R1 staining and survival. (A) Survival plot of patients affected by colorectal cancer acc. to TRAIL-R1 staining intensity. In this and
the following graphs censored cases are indicated by a cross. (B) survival curves of the same patients’ population categorized according to TRAIL-R1
staining on cell membrane. (C) Survival plot of patients according to the staining intensity for TRAIL-R2 (strong vs. weak expression). (D) survival plot
of the same patient’s population categorized according to TRAIL-R2 cellular distribution. (E) Survival of patients according to membrane staining
status of both TRAIL-receptors. Kaplan-Meier curves represent overall survival related to membrane staining of TRAIL receptor 1 and 2 vs. patients
bearing tumors staining negative for both TRAIL receptors.
doi:10.1371/journal.pone.0051654.g004
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TRAIL-R2 in determining patients’ survival in previous studies
reflects the higher prognostic significance of the cellular distribu-
tion of TRAIL-receptors vs. that of their staining intensity.
Clinical consequences of the functional meaning of
TRAIL-receptors staining on cell membranes
Loss of expression of TRAIL-receptors has potential conse-
quences regarding the employment of agonistic antibodies
targeting TRAIL-receptors at this time undergoing clinical
investigation as cancer therapy: although we could confirm that
the vast majority of tumors stained positive for TRAIL-receptors,
we found that loss of TRAIL-receptors on the cell membrane is a
frequent feature of CRC with predominant prognostic signifi-
cance; it should be therefore considered whether failure to show
signs of efficacy in recent clinical trials using TRAIL-receptors
agonistic antibodies [36] might be attributable to insufficient
selection of patients bearing tumors with membrane-bound
TRAIL-receptors. On the other hand, due to the summation of
the prognostic effects of TRAIL-R1 and TRAIL-R2, patients
exhibiting membrane staining for both receptors might profit by
the combined administration of antibodies targeting both recep-
tors or by the administration of recombinant TRAIL [37].
The fact that, independently of their cellular localization, almost
all tumor samples showed some extent of staining for TRAIL-
receptors is in agreement with the notion that genetic loss or
mutation of TRAIL-receptors is a rare event in cancer cells
[34,38]. Differences in the cellular distribution of these receptors
suggests instead that impairment of TRAIL-receptors trafficking to
the outer cell membrane or mechanisms of internalization play a
role in determining the functional loss of TRAIL-receptors. To
this regard, endocytosis mediated by clathrin was recently
described as cause of resistance to TRAIL in breast cancer cells
[18] and several compounds were shown to increase expression of
TRAIL-receptors as well as their localization onto the cell
membranes [39,40]. Internalization of TRAIL-receptors seems
to be therefore a potentially reversible cause for resistance to
TRAIL and administration of such compounds might enhance
apoptosis induction in combination with TRAIL-receptors target-
ing agents [39].
Summary
We propose the analysis of membrane staining for TRAIL-
receptors as prognostic marker in early stage colorectal cancer and
as possible biomarker of response to TRAIL-receptors targeting
agents. Prospectively collected data based on the efficacy of these
compounds will provide a definitive answer to this issue.
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Figure S1 Typical pattern of TRAIL-receptor staining in
normal colonic mucosa showing strong (A,C) or weak
(B,D) staining for TRAIL-R1 and TRAIL-R2 (Original
magnification 6306).
(TIF)
Figure S2 Survival plot of patients affected by colorectal
cancer acc. to: (A) KRAS status, (B) microsatellite status
(MSI=microsatellite instability; MSS=microsatellite
stability), (C) amount of KRAS4A splice variant relative
to KRAS4B. Censored cases are indicated by a cross.
(TIF)
Figure S3 Validation of RT-qPCR based assessment of
KRAS4A and KRAS4B splicing variants. To assess the
validity and efficiency of quantitative PCR analysis performed in
samples isolated from our tissue-specimens, splicing variant
KRAS4A was assessed in cell lines SW948 and HCT15 as
previous immunohistochemical evaluation of these cell lines
showed the maximal differential expression of this splicing variant
of KRAS between these two cell lines (Abubaker et al. J Pathol
2009; 219: 435–445). As shown in panel A, accordingly to this
previous report, KRAS4A production was about sevenfold higher
in SW948 than in HCT15 cells. Moreover, the dynamic range of
the measurement was very high as the calibration curves displayed
linear slopes and linearity was granted for at least four log-scales
down to 100 molecules (panel B).
(TIF)
Table S1 Correlation between TRAIL-receptors stain-
ing intensity and clinico-pathological variables in tumor
samples.
(PDF)
Table S2 Correlation between membrane staining of
TRAIL-receptors and clinico-pathological variables in
tumor samples.
(PDF)
Table S3 PCR primers.
(DOC)
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Table 2. Multivariate survival analysis including TRAIL-R1 and
TRAIL-R2 membrane staining, staining intensity and relevant
clinico-pathological variables.
Variable Relative risk p
(95% confidence
interval)
TRAIL-R1
membrane staining
Positive 162 (70%) 1.00
Negative 69 (30%) 2.06 (1.12–3.77) 0.019
TRAIL-R2
membrane staining
Negative 204 (88%) 1.00
Positive 27 (12%) 3.63 (1.11–11.84) 0.033
TRAIL-R1 staining
intensity
Strong staining 87 (38%) 1.00
Weak/no staining 144 (62%) 1.62(0.65–4.05) 0.302
Gender
Male 126 (55%) 1.00
Female 105 (45%) 0.88 (0.49–1.56) 0.651
Age, y
,65 84 (36%) 1.00
$65 147 (64%) 1.20 (0.65–2.20) 0.555
T-category
T2 34 (15%) 1.00
T3 197 (85%) 1.07 (0.488–2.35) 0.865
doi:10.1371/journal.pone.0051654.t002
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